RxDoctor Payments Data

Sherri English, MD

Family Medicine · San Francisco, CANPI 1710340195

Payments from drug & device makers

$1,980in general payments, 2019–2025

Across 81 payments — averaging $24.45 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Amgen$604
  • AbbVie$423
  • Pfizer$145
  • Exact Sciences$128
  • Novo Nordisk$120
  • Novartis$101
  • plus $460 from 15 others

What the payments were for

  • Food & beverage$1,980100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

22
23
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,980 in reported general payments places this provider in the 80th percentile of 10,533 family medicine providers in California.

See all family medicine providers in California

Medicare billing

Part B allowed, 2024
$140,476
Medicare patients
266
Services billed
3,093

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MounjaroTirzepatide58$68,254
OzempicSemaglutide66$62,142
Repatha SureclickEvolocumab28$29,568
RybelsusSemaglutide24$20,267
EliquisApixaban28$18,222
JardianceEmpagliflozin17$15,425
XareltoRivaroxaban12$11,071
Trelegy ElliptaFluticasone/Umeclidin/Vilanter13$8,491
Rosuvastatin Calcium123$1,475
Atorvastatin Calcium176$1,314
Ezetimibe42$1,023
Losartan Potassium103$916
SynthroidLevothyroxine Sodium12$883
Levothyroxine Sodium160$829
Bupropion XlBupropion Hcl29$638

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Rybelsus$120$82,40990 claims
Lilly USA, LLCMounjaro$59$68,25458 claims
PfizerEliquis$145$18,22228 claims
GSKTrelegy Ellipta$39$8,49113 claims
AbbVieSynthroid$423$88312 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 10,533 family medicine providers in California.

Other family medicine in San Francisco

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →